Mechanisms of Congenital Heart Disease Caused by NAA15 Haploinsufficiency.

"the ms proteomics data have been deposited to the proteomexchange consortium ( http://proteomecentral proteomexchange org ) via the pride partner repository with the data set identifiers pxd017672 and pxd018013."

"Disclosures None."

"Sources of Funding We gratefully acknowledge the National Heart, Lung, and Blood Institute Pediatrics Cardiac Genomics Consortium (PCGC) and Cardiovascular Development Consortium (CVDC) investigators (B.D. Gelb, W.K. Chung, E. Goldmuntz, G.A. Porter, R.P. Lifton, M. Brueckner, H.J. Yost, B.G. Bruneau, C.E. Seidman, J.G. Seidman) for their support and expertise in cardiovascular development. Funding support for this study was provided by grants to the PCGC and CVDC by the US National Heart Lung and Blood Institute (UM1 HL098123 [B.D. Gelb], U01 HL098153 [EG], UM1HL098179 [B.G. Bruneau], R01 HL151257 [C.E. Seidman], 1UM1HL098166 [J.G. Seidman]), SFARI and the JPB Foundation (W.K. Chung), Harvard Medical School Diversity and Inclusion Dean’s Postdoctoral Fellowship (T. Ward), Stanley J. Sarnoff Cardiovascular Research Foundation (W. Tai), HHMI Medical Research Fellowship (M.Y. Jang), FAPESP number 19/11921-1 and 18/13706-0 (G. Venturini), K. Zhang acknowledges fellowship support from the American Heart Association, award number 17PRE33660967, John S. Ladue Memorial Fellowship at Harvard Medical School (Y. Kim), S. Varland and T.Arnesen were funded by the Research Council of Norway through a FRIPRO mobility grant 261981, which is cofounded by the European Union’s Seventh Framework Programme under Marie Curie grant agreement no 608695, the Research Council of Norway (project 249843), the Norwegian Health Authorities of Western Norway (project F-12540), and the Norwegian Cancer Society. Funding was supported by the Engineering Research Centers Program of the National Science Foundation, no.EEC-1647837(C.S. Chen). K. Gevaert acknowledges support from The Research Foundation—Flanders (FWO), project number G008018N. Funding was supported by the Howard Hughes Medical Institute (C.E. Seidman), and Fondation Leducq 16 CVD 03 (J.G. Seidman)."